Patents Assigned to Genentech
  • TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR
    Publication number: 20130217666
    Abstract: The invention relates to novel compounds of Formula I: wherein A1, A2, A3, A4, A5, A6, R2, R4, R5, R6, R7, R8 and subscripts m and n each has the meaning as described herein. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Application
    Filed: February 15, 2013
    Publication date: August 22, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • METHODS AND COMPOSITIONS FOR PROTEIN LABELLING
    Publication number: 20130216475
    Abstract: A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents.
    Type: Application
    Filed: April 2, 2013
    Publication date: August 22, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • Recombinant Production of Heparin Binding Proteins
    Publication number: 20130217867
    Abstract: A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate.
    Type: Application
    Filed: March 26, 2013
    Publication date: August 22, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • METHODS OF USING CDK8 ANTAGONISTS
    Publication number: 20130217014
    Abstract: Provided herein are CDK8 antagonists and methods of using the same.
    Type: Application
    Filed: February 15, 2013
    Publication date: August 22, 2013
    Applicant: GENENTECH, INC.
    Inventor: GENENTECH, INC.
  • BIOLOGICAL MARKERS FOR IDENTIFYING PATIENTS FOR TREATMENT WITH VEGF ANTAGONISTS
    Publication number: 20130216533
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 22, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • ANTIBODY MODULATORS OF HEPATOCYTE GROWTH FACTOR ACTIVATOR
    Publication number: 20130217862
    Abstract: The invention provides methods and compositions for modulating hepatocyte growth factor activator function.
    Type: Application
    Filed: February 12, 2013
    Publication date: August 22, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • Anti-VEGF antibodies
    Patent number: 8512699
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: August 20, 2013
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Anti-Notch3 antibodies
    Patent number: 8513388
    Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: August 20, 2013
    Assignee: Genentech, Inc.
    Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
  • Tmem27 antibody
    Patent number: 8512704
    Abstract: The present invention relates to an antibody directed to a beta cell marker protein, in particular to an antibody directed to the protein TMEM27.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: August 20, 2013
    Assignee: Genentech, Inc.
    Inventors: Kerstin Jahn-Hofmann, Sannah Zoffmann Jensen, Hugues Matile, Cristiano Migliorini, Haiyan Wang
  • ErbB3 ANTIBODIES
    Publication number: 20130209495
    Abstract: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
    Type: Application
    Filed: March 22, 2013
    Publication date: August 15, 2013
    Applicant: GENENTECH, INC.
    Inventors: Robert Akita, Mark Sliwkowski
  • COMPOSITION AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20130210116
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: March 19, 2013
    Publication date: August 15, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • TREATMENT WITH ANTI-ErbB2 ANTIBODIES
    Publication number: 20130209459
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 15, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • R-SPONDIN TRANSLOCATIONS AND METHODS USING THE SAME
    Publication number: 20130209473
    Abstract: Provided are therapies related to the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: February 11, 2013
    Publication date: August 15, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20130203732
    Abstract: Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 8, 2013
    Applicant: GENENTECH, INC.
    Inventor: GENENTECH, INC.
  • Bioerodible polymers for injection
    Patent number: 8501216
    Abstract: A composition for administration of a beneficial agent, contains a solvent mixture including a hydrophobic solvent and a hydrophilic solvent; a bioerodible polymer; and a beneficial agent. The polymer and the beneficial agent are dissolved. The composition has a low viscosity, allowing for easy injection through standard hypodermic needles.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: August 6, 2013
    Assignee: Genentech, Inc.
    Inventors: Jeffrey L. Cleland, Franklin Okumu
  • Diazacarbazoles and methods of use
    Patent number: 8501765
    Abstract: The invention relates to 1,7-diazacarbazole compounds of Formula (I), which are useful as kinase inhibitors, more specifically useful as checkpoint kinase I (chk1) inhibitors, thus useful as cancer therapeutics.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: August 6, 2013
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Hazel Joan Dyke, Charles Ellwood, Emanuela Gancia, Lewis J. Gazzard, Simon Goodacre, Samuel Kintz, Joseph Lyssikatos, Calum MacLeod, Karen Williams
  • ERBB3 Mutations In Cancer
    Publication number: 20130195870
    Abstract: The present invention concerns somatic ErbB3 mutations in cancer including methods of identifying, diagnosing, and prognosing ErbB3 cancers, as well as methods of treating cancer, including certain subpopulations of patients.
    Type: Application
    Filed: November 29, 2012
    Publication date: August 1, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • Compositions with Hematopoietic and Immune Activity
    Publication number: 20130195885
    Abstract: The present invention provides methods of using Bv8 and EG-VEGF polypeptides and nucleic acids to promote hematopoiesis. Also provided herein are methods of screening for modulators of Bv8 and EG-VEGF activity. Furthermore, methods of treatment using Bv8 and EG-VEGF polypeptides or Bv8 and EG-VEGF antagonists are provided.
    Type: Application
    Filed: August 3, 2012
    Publication date: August 1, 2013
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Jennifer LeCouter
  • ARTICLES OF MANUFACTURE AND METHODS FOR CO-ADMINISTRATION OF ANTIBODIES
    Publication number: 20130195851
    Abstract: The present invention relates to articles of manufacture and methods for co-administration of antibodies and/or antibody-like molecules, and further concerns methods for intravenous administration of more than one antibody and/or antibody-like molecule to a subject in need from a stable mixture contained in the same article of manufacture, such as an intravenous infusion bag (IV bag).
    Type: Application
    Filed: December 21, 2012
    Publication date: August 1, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20130195847
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: September 4, 2012
    Publication date: August 1, 2013
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny